论文部分内容阅读
[目的]通过检测非小细胞肺癌患者中HGF、c-Met和p-Met的表达情况,分析其与临床病理特征关系,并与EGFR表达的相关性。[方法]收集经手术切除非小细胞肺癌患者的标本100例,采用免疫组化方法检测HGF、c-Met、p-Met蛋白的表达水平,并收集这些患者既往检测EGFR的表达情况。[结果]HGF阳性表达率为64%,c-Met阳性表达率为47%,p-Met阳性表达率为3%。HGF、c-Met的表达与吸烟状态、年龄、性别、临床分期、分化程度、病理类型均无统计学差异;p-Met阳性表达患者均为EGFR突变的HGF强表达的腺癌患者。HGF、c-Met的表达水平与EGFR表达水平无相关性。[结论 ]HGF、c-Met的阳性表达与吸烟状态、年龄、性别、临床分期、分化程度、病理类型以及EGFR的表达水平均无关。p-Met的阳性表达患者均为HGF强表达的腺癌EGFR突变型。
[Objective] To investigate the relationship between the expression of HGF, c-Met and p-Met in non-small cell lung cancer (NSCLC) patients with clinicopathological features and with the expression of EGFR. [Methods] 100 cases of patients with surgically resected non-small cell lung cancer were collected. The expression of HGF, c-Met and p-Met protein were detected by immunohistochemistry and the expression of EGFR in these patients was collected. [Results] The positive rate of HGF was 64%, the positive rate of c-Met was 47% and the positive rate of p-Met was 3%. There was no significant difference in the expression of HGF and c-Met with the smoking status, age, sex, clinical stage, differentiation degree and pathological type. The patients with positive p-Met expression were EGFR-mutated HGF-overexpressing adenocarcinoma patients. The expression of HGF and c-Met had no correlation with the expression of EGFR. [Conclusion] The positive expression of HGF and c-Met has no relation with the smoking status, age, sex, clinical stage, differentiation degree, pathological type and the expression level of EGFR. The positive expression of p-Met in patients with strong EGFP EGFR mutant adenocarcinoma.